Stock IdeasStrong Buy StocksStrong Buy Stocks from Top Wall Street AnalystsLatest stocks with a Strong Buy rating from the top performing 25% of analysts tracked by WallStreetZen
Stock IdeasStrong Buy Stocks
| Analyst / Firm | Company | Price | Rating | Price Target | Upside/Downside | Date |
|---|---|---|---|---|---|---|
Editas Medicine IncEDIT | $3.04 | Strong Buy | $4.00 | +31.58% | a day ago | |
Analyst RankingTop 3% #112 out of 5269 analysts Average Return+23.83% Win Rate46%130 out of 280 Risk vs RewardPoor Good Analyst ColorChardan Capital's Geulah Livshits raised their price target on Editas Medicine (NASDAQ: EDIT) by 14.3% from $3.5 to $4 on 2026/05/06. The analyst maintained their Strong Buy rating on the stock. Editas Medicine reported its Q1 2026 earnings. Raising their price target on a favorable backdrop for EDIT-401's development, Livshits said that management reaffirmed key EDIT-401 milestones. | ||||||
Tesla IncTSLA | $800.00 | Strong Buy | $850.00 | +6.25% | a day ago | |
Upgrade to Premium to View MoreStrong buys: Upgrade to Premium to view the rest of today's Strong Buy stocks from Wall Street's top analysts Already have access to Premium? Sign In | ||||||
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.